Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)
Singapore
· Delayed Price · Currency is SGD · Price in USD 2.250
-0.010 (-0.44%)
Mar 28, 2025, 4:45 PM SGT
SGX:T14 Revenue
In the year 2024, Tianjin Pharmaceutical Da Ren Tang Group Corporation had annual revenue of 7.31B CNY, down -11.14%. Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of 1.70B in the quarter ending December 31, 2024, a decrease of -30.19%.
Revenue
7.31B CNY
Revenue Growth
-11.14%
P/S Ratio
n/a
Revenue / Employee
1.58M CNY
Employees
4,619
Market Cap
3.84B SGD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.31B | -915.58M | -11.14% |
| Dec 31, 2023 | 8.22B | -26.94M | -0.33% |
| Dec 31, 2022 | 8.25B | 1.34B | 19.42% |
| Dec 31, 2021 | 6.91B | 303.89M | 4.60% |
| Dec 31, 2020 | 6.60B | -390.23M | -5.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definition